Observational studyESC heart failure2026
Cardiac disease in patients with inflammatory myopathy.
Observational study in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsInflammatory myopathies (IMs) are a group of autoimmune diseases characterized by progressive symmetric muscle weakness and various extramuscular manifestations. Cardiac involvement in IM has been associated with worse outcomes, but evidence to support specific screening and management algorithms for cardiac comorbidities in IM is still limited.
methodsFor this observational study, 37 adult IM patients recruited from the rheumatology outpatient clinic at Ludwig-Maximilians-University Hospital between August 2023 and January 2025 completed a questionnaire on IM characteristics, management, clinical events, and cardiac disease. Self-reported data were verified and complemented using clinical records. The main study endpoints included the incidence of cardiomyopathy, documented cardiac arrhythmias, and myocardial infarction following the diagnosis of IM.
resultsThe median age at last follow-up was 60 years and 35.1% were male. The most common cardiac symptoms reported by study participants included dyspnoea (45.9%), congestion/oedema (40.5%), palpitations (32.4%), and chest pain (18.9%). Arterial hypertension was diagnosed in 27% after IM had been established. Supraventricular and ventricular arrhythmias were documented in 10.8% and 5.4%, respectively. Echocardiography was performed in all study participants, revealing left ventricular diastolic dysfunction in 35.1%. Severe structural heart disease and cardiac adverse events, including acute myocardial infarction, severe valvular disease, and left ventricular systolic dysfunction, were documented only in isolated cases of IM.
conclusionsCardiac symptoms, risk factors, and structural abnormalities are prevalent in a substantial proportion of patients with IM. Routine cardiologic assessment, including echocardiography, may be advisable. Further evidence from prospective longitudinal studies is needed to optimize screening algorithms and multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.